[PEGS 2021] Accelerating Development of Therapeutic Interventions for COVID-19

Year:
2021

Watch Recorded Presentation

Gaurav Agrawal, Ph.D.
Scientific Development Manager
 
Abstract
Millions of deaths worldwide have been attributed to COVID-19, caused by the SARS-CoV-2 virus. The high mortality rate has been associated with cytokine release syndrome, commonly referred to as cytokine storm, which is an excessive and dysregulated production of proinflammatory cytokines by patient’s immune system. As a treatment strategy, a vast array of anti-inflammatory therapies are being explored and currently there are numerous clinical programs ongoing focused on developing and repurposing therapeutic drugs for treatment of COVID-19. In this talk, we highlight how our functional cell-based assays are supporting these programs, particularly in managing proinflammatory cytokines associated with high mortality rate in COVID-19 patients. We will present case studies for our target-specific, ready-to-plate qualified Bioassays, and discuss how they can accelerate drug development and QC lot release programs for biologic drugs for COVID-19